Intensity Therapeutics, Inc. operates as biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
50.0%
招募中
1
50.0%
暂无批准数据
- Intensity Therapeutics is advancing INT230-6, an intratumoral therapy combining cisplatin and vinblastine with a diffusion enhancer, designed to saturate dense solid tumors while largely avoiding systemic exposure. - The localized approach kills tumor cells directly and triggers a personalized systemic immune response, effectively creating an anti-cancer vaccine from the patient's own tumor that can target both injected and distant metastases. - INT230-6 addresses a key limitation of intravenous immunotherapies by overcoming the "cold" tumor barrier and the Catch-22 of dose-dependent off-target toxicities that damage healthy organs. - Founder and CEO Lew Bender emphasized that the goal is to help patients live longer without permanent harm from treatment, calling the platform a potential solution to the half-century problem of viable intratumoral cancer therapy.
- Storm Therapeutics raised $56 million in Series C funding from investors including Pfizer Ventures, Taiho Ventures, and Fast Track Initiative to advance STC-15, a first-in-class METTL3 inhibitor. - The company has dosed the first patient in a Phase II monotherapy study evaluating STC-15 in select sarcoma subtypes, with plans for a combination study with toripalimab. - STC-15 demonstrated durable tumor regression across multiple sarcoma subtypes in Phase I trials by targeting METTL3, an RNA-modifying enzyme critical for cancer stem cell differentiation. - The Phase II study is designed to support a potential accelerated regulatory approval pathway for STC-15 and establish foundation for development in additional oncology indications.
- Intensity Therapeutics received US Patent Number 12,496,345 for its intratumoral cancer treatment method, expanding its intellectual property portfolio to 19 issued patents across 41 countries. - The company's lead compound INT230-6 combines cisplatin and vinblastine sulfate with a proprietary diffusion enhancer to deliver cytotoxic agents directly into tumors while triggering immune responses. - Clinical trials have enrolled over 200 patients, with ongoing Phase 3 studies in soft tissue sarcoma and Phase 2 trials in triple-negative breast cancer showing the technology's potential to transform cancer treatment paradigms.
- Intensity Therapeutics' INVINCIBLE-4 Phase 2 study shows 71.4% pathological complete response rate with INT230-6 plus standard care versus 33% with standard care alone in triple-negative breast cancer patients. - The combination therapy demonstrated 44% fewer grade 3 or higher adverse events compared to standard immunochemotherapy alone, suggesting improved safety profile. - The company has submitted a protocol amendment to Swiss regulators to resume enrollment after addressing skin irritation issues with modified dosing parameters. - Results support INT230-6's potential for FDA accelerated approval pathway, as pathological complete response is an accepted surrogate endpoint for high-risk breast cancer.
- Intensity Therapeutics' INVINCIBLE-4 Phase 2 trial shows INT230-6 plus standard of care resulted in 50% fewer grade 3 or higher adverse events compared to standard chemotherapy alone in triple negative breast cancer patients. - The company is modifying the dosing protocol to a single injection at lower volumes after observing skin and tissue necrosis in some patients who received two doses of INT230-6. - Intensity plans to pursue a potential Phase 3 trial design that could eliminate the cardiotoxic anthracycline doxorubicin from treatment regimens while maintaining efficacy. - The intratumoral injection therapy INT230-6 combines cisplatin and vinblastine with a penetration enhancer to kill tumors locally while triggering systemic immune responses.
- Intensity Therapeutics' stock jumped 394.4% after INT230-6 demonstrated a 75% disease control rate across more than 20 cancer types in a Phase I/II trial. - The intratumoral therapy showed median overall survival of 11.9 months compared to historical controls of 4-7 months, with particularly strong results in metastatic sarcoma patients at 21.3 months. - Patients receiving higher doses showed abscopal effects in at least 20% of cases, with uninjected tumors shrinking and increased immune cell infiltration observed. - The company has initiated Phase III trials including INVINCIBLE-3 for sarcoma and plans a study in triple-negative breast cancer based on these encouraging results.
- Intensity Therapeutics published phase 1/2 clinical results for INT230-6 in eBioMedicine, showing a 75% disease control rate and 11.9-month median overall survival in heavily pretreated patients with advanced metastatic cancers. - Patients receiving INT230-6 at doses treating >40% of tumor burden achieved 83.3% disease control rate and 18.7-month median survival compared to 50% and 3.1 months in the <40% group. - The intratumoral therapy demonstrated abscopal effects in approximately 20% of patients and increased activated T-cell infiltration in tumor microenvironments without dose-limiting toxicities. - Based on these results across over 20 cancer types, the company has initiated a Phase 3 trial in soft tissue sarcoma and additional randomized controlled studies.
- Intensity Therapeutics completed a $4 million registered direct offering to fund advancement of clinical trials for its novel intratumoral cancer therapies. - The company's proprietary non-covalent conjugation technology is designed to kill tumors and enhance immune system recognition of cancers. - The funding extends the company's cash runway until the end of the first quarter of 2027, supporting continued development of its late-stage clinical programs.
- Intensity Therapeutics has priced a $2.35 million public offering to fund ongoing clinical trials of its novel intratumoral cancer therapy INT230-6, which has shown promise in killing tumors and triggering immune responses. - The offering includes 3.13 million shares of common stock with accompanying warrants at $0.75 per share, with proceeds primarily directed toward the INVINCIBLE-3 and INVINCIBLE-4 clinical studies targeting soft tissue sarcoma and triple-negative breast cancer. - INT230-6 represents a potentially paradigm-shifting approach to cancer treatment through direct intratumoral injection, having already demonstrated efficacy in clinical trials with over 200 patients across multiple cancer types.
- Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development. - FDA grants Orphan Drug Designation to Actuate Therapeutics' elraglusib for soft tissue sarcoma treatment, highlighting its potential to address unmet needs in this rare cancer. - Novel approaches include tumor-targeting antibody-cytokine fusion proteins, intratumoral administration techniques, and GSK-3β inhibition, offering hope for improved outcomes in this challenging disease.
